Where is I-Mab headquartered?

I-Mab is located in Pudong, shanghai municipality.

Who invested in I-Mab?

I-Mab has 13 investors including Geekdom Fund And Geekdom Fund.

When was the last funding round for I-Mab?

I-Mab closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

i-mabbiopharma.com

I-Mab

I-Mab is a China-based biopharmaceutical company that develops and commercializes biological therapeutics for the treatment of cancer and autoimmune disorders.

Business Model:

Revenue: $13.8M

Employees: 201-500

Geographic Data

Address: 88 Shangke Road

City: Pudong

State: shanghai municipality

Zip: 201210

Country: CN

Financial Info

Stage:

post ipo equity

Raised Last:

$418M

Raised Total:

$815M

Social

Twitter

Crunchbase

Metrics

3,227,437Website Global Rank

4,872Website Monthly Traffic

Twitter Followers

Description

I-Mab is a China-based biopharmaceutical company that develops and commercializes biological therapeutics for the treatment of cancer and autoimmune disorders.

Contact Phone:

Contact Email:

IPO Details

I-Mab went public on 1/16/2020 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
1/16/2020

Ticker Symbol:
IMAB

IPO Price:
$14/share

Amount Raised:
$104M

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
9/2019	Series C		-
3/2017	Series B		$0	C-Bridge Capital Genexine Tasly Pharmaceutical C-Bridge Capital Genexine Tasly Pharmaceutical
1/2020	IPO		$127.8M
9/2020	Post-IPO Equity		$0	Alyeska Investment Group Avidity Partners Cormorant Asset Management GIC Hillhouse Capital Group Invus Lake Bleu Capital Octagon Capital Partners OrbiMed Perceptive Advisors Sphera Global Healthcare Fund Alyeska Investment Group Avidity Partners Cormorant Asset Management GIC Hillhouse Capital Group Invus Lake Bleu Capital Octagon Capital Partners OrbiMed Perceptive Advisors Sphera Global Healthcare Fund
6/2018	Series C		$0	Ally Bridge Group C-Bridge Capital CDH Investments EDBI Hillhouse Capital Group Hony Capital HOPU Investment Management Company Tally Capital Tasly Pharmaceutical Ally Bridge Group C-Bridge Capital CDH Investments EDBI Hillhouse Capital Group Hony Capital HOPU Investment Management Company Tally Capital Tasly Pharmaceutical
10/2016	Series A		-	C-Bridge Capital C-Bridge Capital
7/2019	Series C	1	$27M	VMS Asset Management VMS Asset Management
9/2020	Private Placement	11	$418M	Hillhouse GIC OrbiMed Octagon Capital Advisors Invus Lake Bleu Capital Perceptive Advisors sphere Healthcare Alyeska Investment Group, L.P Alyeska Investment Group Avidity Partners Cormorant Asset Management GIC Hillhouse Capital Group Invus Lake Bleu Capital Octagon Capital Partners OrbiMed Perceptive Advisors Sphera Global Healthcare Fund
9/2019	Series C		-	WuXi Biologics Tigermed WuXi Biologics Tigermed
6/2018	Series C	9	$220M	Hony Capital (Beijing) Co., Ltd. Hillhouse Capital Group CDH Investment Ally Bridge Group EDBI C-Bridge Capital Hony Capital
3/2017	Series B	3	$150M	C-Bridge Capital
10/2016	Series A	1	-	C-Bridge Capital C-Bridge Capital

Acquisitions

Announced Date	Name	Price
3/2017	Tianjing Biotechnology (Shanghai) Co

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details